Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) has appointed Sean Maenpaa as Senior Vice President, Business Development, effective October 12, 2026, according to a company statement.

Maenpaa will oversee out-licensing, partnering, collaboration transactions, in-licensing opportunities, and corporate development strategy for Actinium's targeted radiotherapy pipeline.

Maenpaa brings more than 20 years of experience in oncology business development and commercial leadership across the radiopharmaceutical sector. He previously served as Managing Director of Maenpaa Consulting LLC, providing strategic support to private equity and investment banks focused on oncology radiopharmaceuticals.

Before his consultancy, Maenpaa was Vice President, Commercial, at BWXT Medical, where he oversaw business development and sales for more than $120 million in medical radioisotope supplies. At Telix Pharmaceuticals, as Vice President, Global Commercial, he contributed to driving global sales of ILLUCCIX® to $320 million. As Head of Business Development and Global Commercialization at Clovis Oncology, he led licensing initiatives and contributed to the divestment of Lutetium-177 FAP2286 to Novartis. At Bayer AG, he managed a portfolio of thorium alpha radioligand therapies and supported the acquisition of Ac-225 PSMA Trillium Macropa from Ratio Therapeutics.

Earlier in his career, Maenpaa held a senior commercial role at Novartis, leading strategy for a 12-asset hematology pipeline, and began his career at Celgene, where he participated in U.S. and European launches of Revlimid® in Multiple Myeloma and MDS.

Maenpaa holds an MBA from the University of Sheffield and a BSc in Pharmacology from the University of Liverpool.